Scott R Anderson, Malek Ayoub, Sarah Coats, Scott McHenry, Tingyi Tan, Parakkal Deepak
{"title":"Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.","authors":"Scott R Anderson, Malek Ayoub, Sarah Coats, Scott McHenry, Tingyi Tan, Parakkal Deepak","doi":"10.14309/ajg.0000000000003208","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The safety and effectiveness of glucagon-like peptide receptor agonists (GLP1-RA) in patients with inflammatory bowel disease (IBD) are poorly understood.</p><p><strong>Methods: </strong>Patients with IBD treated with GLP1-RA were retrospectively identified for outcomes of adverse events, weight change, and clinical, endoscopic, and biomarker response.</p><p><strong>Results: </strong>Among a total of 120 patients with IBD, gastrointestinal side effects being the most common (11.5%). Semaglutide showed the most significant weight reduction. C-reactive protein levels decreased after one year ( P = 0.005). No differences were observed in IBD-related hospitalizations or endoscopic scores.</p><p><strong>Discussion: </strong>GLP1-RA therapy appears safe and effective, with an associated C-reactive protein reduction, in patients with IBD.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"1152-1155"},"PeriodicalIF":8.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14309/ajg.0000000000003208","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The safety and effectiveness of glucagon-like peptide receptor agonists (GLP1-RA) in patients with inflammatory bowel disease (IBD) are poorly understood.
Methods: Patients with IBD treated with GLP1-RA were retrospectively identified for outcomes of adverse events, weight change, and clinical, endoscopic, and biomarker response.
Results: Among a total of 120 patients with IBD, gastrointestinal side effects being the most common (11.5%). Semaglutide showed the most significant weight reduction. C-reactive protein levels decreased after one year ( P = 0.005). No differences were observed in IBD-related hospitalizations or endoscopic scores.
Discussion: GLP1-RA therapy appears safe and effective, with an associated C-reactive protein reduction, in patients with IBD.
期刊介绍：
Published on behalf of the American College of Gastroenterology (ACG), The American Journal of Gastroenterology (AJG) stands as the foremost clinical journal in the fields of gastroenterology and hepatology. AJG offers practical and professional support to clinicians addressing the most prevalent gastroenterological disorders in patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
